Johnson & Johnson stock pre-market at EUR 230.38: minus 0.63 percent
Published on 10/08/2026 at 08:17 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Johnson & Johnson stock was at EUR 230.38 in pre-market trading at Lang & Schwarz at 8:16 a.m. CEST on October 8, 2026. That was down 0.63 percent versus the Lang & Schwarz close of EUR 231.83 on October 7, 2026.
Pre-market trading
The Lang & Schwarz bid was EUR 230.15 and the ask was EUR 230.60. The further course from the Xetra open at 9:00 a.m. CET/CEST is shown by the continuously updated real-time quote of Johnson & Johnson stock.
Recent clinical update
In a release dated October 2, 2026, Johnson & Johnson announced two-year data from the Phase 3 ICONIC-TOTAL study of ICOTYDE in plaque psoriasis. At Week 112, 70 percent of treated patients had clear or almost clear skin; site-specific complete clearance was reported for 60 percent of patients with scalp psoriasis, 89 percent with genital psoriasis and 63 percent with psoriasis affecting the hands or feet.
Vision-health survey
In an October 1, 2026 release distributed by Business Wire, Johnson & Johnson said a global survey of 6,000 women found that 40 percent connected eye changes with menopause, while 90 percent said clear and comfortable vision supported their confidence or sense of self. The release said 18 percent had booked an annual eye exam as part of their midlife routine.
